Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Auron Presents Preclinical Data Highlighting the Activity of AUTX-703 in Prostate Cancer at 2025 AACR Annual Meeting

NEWTON, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Auron Therapeutics, a clinical-stage biotechnology company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory disease, today announced preclinical data in prostate cancer at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, IL.

Using a series of experiments, Auron demonstrated activity with AUTX-703, its oral, potent and selective degrader targeting KAT2A/B in cell lines and patient derived organoid models (PDXO) of neuroendocrine prostate cancer (NEPC) and castrate resistant prostate cancer (CRPC). In NEPC cell lines and PDXO models treated for up to 21 days, AUTX-703 mediated potent KAT2A/KAT2B degradation, inhibited cell growth and induced cell state differentiation. AUTX-703 alone or in combination with enzalutamide was also found to induce cell differentiation in androgen receptor (AR) sensitive and AR resistant prostate cancer cell lines. These data support advancing AUTX-703 into clinical development for multiple sub-types of prostate cancer.

“These preclinical data show that AUTX-703 can effectively inhibit growth in multiple prostate cancer models, offering a novel approach to tackling these challenging cancers by targeting cell-state plasticity through KAT2A/B degradation,” said Kate Yen, Ph.D., Founder and Chief Executive Officer of Auron. “As we advance our first Phase 1 clinical trial in hematologic malignancies, these findings reinforce our confidence in AUTX-703’s potential to offer meaningful benefits to patients with multiple tumor types facing limited options.”

About Auron Therapeutics

Auron Therapeutics is a platform-powered, product-driven company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory disease. Auron pioneered its AURIGIN™ platform, which uses AI and machine learning to compare cell states and identify novel drug targets, optimal development models, and biomarkers to facilitate proper patient selection, ultimately accelerating the development of effective and durable therapies. Using AURIGIN, the Company is building a pipeline of small molecule targeted therapies, led by a first-in-class, oral KAT2A/B degrader, AUTX-703, which is being developed for the treatment of both hematologic malignancies and solid tumors. For more information, please visit aurontx.com and follow us on LinkedIn.

Investor Contact:

Renee Leck
THRUST Strategic Communications
renee@thrustsc.com        

Media Contact:

Carly Scaduto
Carly Scaduto Consulting
Carly@carlyscadutoconsulting.com


Primary Logo

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.